Unhappy New Year For Incyte With Itacitinib Flop
JAK1 Inhibitor Fails In Steroid-Naiïve Acute GVHD
Incyte's hopes of reducing its reliance on Jakafi have suffered a blow after a Phase III trial of itacitinib failed. The stock has slumped and analysts are raising concerns about the company's ability to generate value from its hefty R&D investments.
You may also be interested in...
Six of seven mid-sized companies enjoyed valuation increases over the first quarter, with four firms up by 7.5% or more. Some are benefiting from direct involvement in addressing the COVID-19 pandemic.
Biotech hopes this initial approval will be followed by approvals of Pemazyre in bladder cancer, first-line cholangiocarcinoma and possibly even a tumor-agnostic indication for FGFR-mutated cancers.
Stock market reaction to the first day’s news from the 38th J.P. Morgan Healthcare conference in San Francisco was negative, probably because expectations for a continuation of December’s bumper M&A bonanza were too high.